Trial · NCT04933799
IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.
NCT04933799, Phase 2, Unknown, Giovanni Franchin, M.D, Ph.D
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation. Trials, record NCT04933799. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04933799
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.
- NCT number
- NCT04933799
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 68 participants, estimated
- Lead sponsor
- Giovanni Franchin, M.D, Ph.D
- Conditions
- COVID-19 Pneumonia
- Interventions
- PF-06650833, Matching Placebo
- First posted
- 2021-06-22
- Last updated
- 2021-06-22
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Worsening based on the NIAID Ordinal scale | 29 days | Proportion of subjects worsened at end of treatment (Day 29), as defined by categories 7 and 8 in the 8-point NIAID scale of disease severity. 1. Not hospitalized, no limitations on activities. 2. Not hospitalized, limitation on activities and/or requiring home oxygen\*. 3. Hospitalized, not requiring supplemental oxygen\* - no longer requires ongoing medical care. 4. Hospitalized, not requiring supplemental oxygen\* - requiring ongoing medical care (COVID-19 related or otherwise). 5. Hospitalized, requiring supplemental oxygen\*. 6. Hospitalized, on non-invasive ventilation or high-flow oxygen devices\*\*. 7. Hospitalized, on invasive mechanical ventilation or ECMO. 8. Death. * For subjects on chronic home O2 supplementation (pre-morbid state), supplemental O2 is defined as ≥ home O2 requirement. * Use of non-invasive ventilation for chronic conditions (eg, Obstructive sleep apnea \[OSA\]) is not applicable. |
| Secondary | Improvement based on the NIAID Ordinal scale | 29 days | Proportion of subjects improved at end of treatment (Day 29), as defined by categories 1, 2, 3, and 4 in the 8-point NIAID ordinal scale of disease severity. |
| Secondary | Recovered based on the NIAID Ordinal scale | 29 days | Proportion of subjects recovered at end of treatment (Day 29), as defined by categories 1, 2, and 3 in the 8-point NIAID ordinal scale of disease severity. |
| Secondary | mortality | 29 days | All-cause mortality at Day 29 |
| Secondary | mortality | 61 days | All-cause mortality at Days 61 |
| Secondary | Time to clinical improvement based on the NIAID Ordinal scale | 29 days | Time to clinical improvement (defined as an at least 1-point decrease on the 8-point NIAID ordinal scale of disease severity). |
| Secondary | Time to worsening based on the NIAID Ordinal scale | 29 days | Time to worsening (defined as an at least 1-point increase on the 8-point NIAID ordinal scale of disease severity) |
| Secondary | Percentage of subjects in each category of ordinal scale of disease severity | 29 days | Percentage of subjects in each category of the 8-point NIAID ordinal scale of disease severity at Days 3, 5, 8, 11, 15, 22, and 29 |
| Secondary | Change in disease severity based on the NIAID Ordinal scale | 29 days | Change in the 8-point NIAID ordinal scale of disease severity from Day 1 to Days 3, 5, 8, 11, 15, 22, and 29, as available. Higher score means worsening outcomes. |
| Secondary | mechanical ventilatory support | 29 days | Proportion of subjects that have required mechanical ventilatory support through Day 29. |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04933799
GET https://conductscience.org/api/trials/v1/NCT04933799/registered?page=2